Hypertension and heart failure in Primary Care and cardiology consultations of in Spain;Hipertensión arterial e insuficiencia cardíaca en las consultas de Atención Primaria y de Cardiología en España

Revista Clinica Espanola

Volumn 203, Issue 7, 2003, Pages 334-342

  Barrios Alonso, V ^b   Pena Perez G ^b   Gonzalez Juanatey J R ^b   Alegria Ezquerra E ^b   Lozano Vidal, J V ^a   Llisterri Caro, J L ^a   Gonzalez Maqueda I ^b  

^a Soc Espanola Med Rural/Generalista   (Spain)

^b Agencia de Investigación Y Sección de Hipertensión Arterial   (Spain)

Author keywords

Heart failure; Hypertension; Primary care; Treatment

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; NITRATE; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL STUDY; CONSULTATION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT INFORMATION; PRESCRIPTION; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; RISK FACTOR; SPAIN; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

EID: 0038383171     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. The task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
2. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure. Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001;104:2996-3007.
3. Swedberg K, Kjekshus J, Snapin for the CONSENSUS investigators. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 1999;20:136-9.
4. Barrios V, Ortega J. ACE inhibitors in the treatment of heart failure. Heart Failure Train Lett 1999;7:2-5.
5. Navarro-López F, De Teresa E, López Sendón JL, Castro Beiras A. Guías del diagnóstico, clasificación y tratamiento de la insuficiencia cardíaca y del shock cardiogénico. Informe del grupo de trabajo de insuficiencia cardiaca de la Sociedad Española de Cardiología. Rev Esp Cardiol 1999;52 (Suppl 2):1-54.
6. Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, et al. Low risk-factor profile and long-term cardiovascular and non-cardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999;282:2012-8.
7. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 1996;156: 1789-96.
8. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-62.
9. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
10. Cutler JA, Psaty BM, MacMahon S, Furberg CD. Public health issues in hypertension control: what has been learned from clinical trials. En: Laragh JH, Brenner, editores. Hypertension: pathophysiology, diagnosis and management. New York: Raven, 1995. p. 253-70.
11. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
12. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17:151-83.
13. Lombera F, Barrios V, Soria F, Placer L, Cruz JM, Tomás L, et al. Guías de práctica clínica de la Sociedad Española de Cardiologâ en hipertensión arterial. Rev Esp Cardiol 2000;53:66-90.
14. Ruilope LM, Barrios V. Pharmacologic treatment in hypertensive heart disease. En: Crawford MH, DiMarco JP, editores. Cardiology. London: Mosby, 2001. p. 8.1-8.8.
15. Rodríguez GC, Llisterri JL, Alonso FJ, Rodríguez L, Barrios V. La insuficiencia cardíaca congestiva en Atención Primaria (1). Concepto, clasificación, epidemiología, etiología, pronóstico, diagnóstico y complicaciones. SEMERGEN 2000;26:5-13.
16. Rodríguez GC, Llisterri JL, Alonso FJ, Barrios V, Rodríguez L. La insuficiencia cardíaca, congestiva en Atención Primaria (2). Tratamiento, criterios de derivación y seguimiento. SEMERGEN 2000;26:66-76.
17. NHANES I Epidemiologic follow-up study. Risk factors for congestive heart failure in US men and women. Arch Intern Med 2001;161:996-1002.
18. Van den Hoogen PCW, Feskens EJM, Nagelkerke NJD, Menotti A, Nissinen A, Kromhout D, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med 2000;342:1-8.
19. Burt VL, Culter JA, Higgins M, Horan MJ, Labarthe D, Whelton P, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995;26:60-9.
20. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998;16:747-52.
21. Alli C, Avanzini F, Bettelli G, Colombo F, Torri V, Tognoni G. The long-term prognostic significance of repeated blood pressure measurements in the elderly: SPAA (Studio sulla Pressione Arteriosa nell'Anziano) 10-year follow-up. Arch Intern Med 1999;159:1205-12.
22. Tomás L, Varas C, Bernades E, Balaguer I. Coronary risk factors and a 20-year incidence of coronary heart disease and mortality in a Mediterranean industrial population. The Manresa Study, Spain. Eur Heart J 1994; 15:1028-36.
23. Grima A, Alegría E, Jover P. Prevalencia, de los factores de riesgo cardiovascular clásicos en una población laboral mediterránea de 3.996 varones. Rev Esp Cardiol 1999;52:910-8.
24. Muñiz J, Juane R. La hipertensión arterial en España. Rev Esp Cardiol 1995; 48 (Suppl 4):3-8.
25. Banegas JR, Rodríguez F, De la Cruz JJ, De Andrés B, Del Rey J. Mortalidad relacionada con la hipertensión y la presión arterial en España. Med Clin (Barc) 1999;112:489-94.
26. Bautista D, Pérez S. Tendencias en la mortalidad por enfermedades cardiovasculares en la Comunidad Valenciana. Rev Esp Cardiol 1997;50:308-13.
27. Gonzélez-Juanatey JR, Alegría E, Lozano JV, Llisterri JL, García JM, González I. Impacto de la hipertensión en las cardiopatías en España. Estudio CARDIOTENS 99. Rev Esp Cardiol 2001;54:139-49.
28. Cowie MR, Wood DA, Coats AJS, Thompson SG, Poole-Wilson PA, Suresh V, et al. Incidence and aetiology of heart failure: a population-based study. Eur Heart J 1999;20:421-8.
29. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, et al. Congestive heart failure in the community. A Study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98:2282-9.
30. Eriksson H, Svardsudd K, Larsson B, Ohlson LO, Tibblin G, Welin L, et al. Risk factors for heart failure in the general population: the study of men born in 1913. Eur Heart J 1989;10:647-56.
31. Mosterd A, Hoes AW, Bruyne MC, Deckers JW, Linker DT, Hofman A, et al. Prevalence of heart failure and left ventricular dysfunction in the general population. The Rotterdam Study. Eur Heart J 1999;20:447-55.
32. Brotons C, Moral I, Ribera A, Pérez G, Cascant P, Bustins M, et al. Tendencias de la morbimortalidad por insuficiencia cardíaca en Cataluña. Rev Esp Cardiol 1998;51:972-6.
33. Rodríguez Artalejo F, Guallar P, Banegas JR, Del Rey J. Trends in hospitalization and mortality for heart failure in Spain 1980-1993. Eur Heart J 1997;18:1771-9.
34. Cowie MR, Mosterd A, Wood, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J 1997;18:208-25.
35. Ho KKL, Pisky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993;22:6A-13A.
36. Rodgers A, MacMahon S. Blood pressure and the global burden of cardiovascular disease. Clin Exp Hypertens 1999;21:543-52.
37. Cruickshank JM, Thorp JM, Zacharias FJ. Benefit and potential harm of lowering high blood pressure. Lancet 1987;1:581-4.
38. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials. JAMA 1995;273:1450-6.
39. Parker M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
40. CIBIS II investigators and committees. The cardiac insufficiency bisoprolol study II: a randomized trial. Lancet 1999;353:9-13.
41. MERIT-HF study group. Effect of the metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 1999;353:2001-7.
42. Packer M, Coats AJS, Fowler, Katus HA, Krum H, Mohacsi P, Jean L, Rouleau JL, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
43. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
44. Edep ME, Shah NB, Tateo IM, Massie BM. Differences between Primary Care and Cardiologist in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol 1997;30:518-26.